BRD4 and sarcoma: Furthermore, phase separation processes, although controversial, may explain why FET sarcoma cells are sensitive to BRD4 inhibition; a recent study suggested that the preferential disruption of super‐enhancer‐driven gene expression by BRD4 inhibitors can be attributed to a preferential partitioning of these drugs into phase‐separated condensates at super‐enhancers [71].